Join the fight against Sepsis | Order Biospecimens Online

Join the fight against Sepsis

Banner Join the fight against Sepsis with human blood samples

Join the fight against Sepsis with human blood samples

According to a recent scientific publication, 20% of global deaths in 2017 were caused by sepsis, with 11 million sepsis related deaths in total. Therefore, sepsis-remains a global health concern due to its high morbidity and mortality rates. This life-threatening condition is caused by the body's overwhelming response to an infection with bacteria, viruses, fungi, or parasites and can result in organ dysfunction. Significant progress has been made in sepsis research and treatment during the last years, whereas early recognition, optimized treatment strategies, and improved patient outcomes were the focus of interest.

New biomarkers and AI improve the speed of diagnosing sepsis

The development of novel biomarkers for early detection is one of the major advances in sepsis research over the past years. High-sensitivity C-reactive protein (hs-CRP), procalcitonin (PCT), and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) made it possible to distinguish sepsis from a non-infectious systemic inflammatory response syndrome (SIRS). These biomarkers enable a rapid diagnosis as well as an early initiation of appropriate treatment measures.

Machine learning algorithms that analyze big data sets contribute to this, as they can help to detect and predict sepsis fast and at an early stage of the disease course. Due to the fast analysis of clinical and laboratory data, those algorithms can not only identify subtle patterns related to the infection but will also help clinical staff with AI-driven decisions that support doctors in making evidence-based treatment choices. With AI playing a more powerful role in the near future, this approach has the potential to revolutionize the detection and treatment of sepsis.

Improved sepsis treatment with combination therapies

As sepsis is characterized by a dysregulated immune response that results in widespread inflammation and tissue damage, recent studies put their focus on immunomodulation therapies aiming to restore immune balance. These therapies include treatment with glycoproteins like interferon-β, which has the potential to reduce inflammation and prevent organ dysfunction. On top of that, therapy with mesenchymal stem cells (MSC) made promises in preclinical studies as they were also able to provide anti-inflammatory effects and tissue-repairing mechanisms.

Recent research studies have explored combination therapies to target different aspects of sepsis simultaneously, where specific combinations of antibiotics, immunomodulators, and adjunctive therapies showing promise to improve the outcomes in certain patient populations.

Nevertheless, the prevention of infection is still a keystone in sepsis management. Improved infection control practices and antimicrobial stewardship have curbed the spread of drug-resistant pathogens and thereby reducing the incidence of sepsis.

Central BioHub is eager to assist scientists in their research to advance in the field of treating bloodstream infections with novel antibiotics and advanced biomarker detection systems. Hence, we offer high-quality plasma and serum samples from sepsis patients that were tested for bacterial infections.


Sepsis Blood samples in detail:


  • Matrix: Plasma and Serum
  • Confirmed infections: E. coli, Pseudomonas, Streptococcus, Staphylococcus
  • Donor details: Clinical profile and demographics

On top of that, customers can apply advanced filters in our expert search that allow them to find sepsis blood samples which will fulfil all their requirements. Reserve your sample for your upcoming biomedical research by clicking on clinical diagnosis, ICD-10 codesand laboratory parameters.

Central BioHub - Order biospecimens online.

Sepsis is a life-threatening condition caused by an overwhelming response of the immune system to an infection of the blood stream. This infection can be triggered by bacteria, viruses, fungi or parasites. Central BioHub offers blood samples of sepsis patients that were tested for an infection with E. coli, Pseudomonas, Streptococcus and Staphylococcus.
In order to control the infection, broad-spectrum antibiotics are administered as early as possible during the course of sepsis. Afterwards, the infection needs to be localized and treated appropriately. Another crucial aspect of treating sepsis is to stabilize the patient´s vital parameters and support affected organs to avoid organ failures.
As an infection will spread quickly throughout the body, early recognition and precise diagnosis are the key elements of a successful treatment. Besides the difficulties of stabilizing the patient body, antibiotic resistance is a major threat for patients with sepsis. Central BioHub is therefore eager to support researchers in discovering new drug targets by supplying them with human sepsis samples to conduct biomedical studies.
The key of preventing sepsis is to avoid infections in the first place by good hygiene practices. On top of that, certain vaccinations and responsible antibiotic stewardship to avoid antibiotic resistance can help to minimize the risk of developing sepsis.